Bimekizumab Versus Secukinumab Continuous Maintenance of Response at Every Visit through One Year in Patients With Moderate to Severe Plaque Psoriasis: Post-Hoc Results from the BE RADIANT Phase 3b Trial. J of Skin 2022, 6 (6), s70. https://doi.org/10.25251/skin.6.supp.70.